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Abstract  27 
The gut microbiota produce hundreds of bioactive compounds, including B-vitamins, which play 28 
significant physiological roles in hosts by supporting the fitness of symbiotic species and suppressing 29 
the growth of competitive species. B-vitamins are also essential to the host and certain gut bacterium. 30 
Although dietary B-vitamins are mainly absorbed from the small intestine, excess B-vitamins unable 31 
to be absorbed in the small intestine are supplied to the distal gut. In addition, B-vitamins are 32 
supplied from biosynthesis by distal gut microbiota. B-vitamins in the distal colon may perform 33 
many important functions in the body; they act as (1) nutrients for a host and their microbiota, (2) 34 
regulators of immune cell activity, (3) mediators of drug efficacy, (4) supporters of survival, or the 35 
fitness of certain bacterium, (5) suppressors of colonization by pathogenic bacteria, and (6) 36 
modulators of colitis. Insights into basic biophysical principles, including the bioavailability of B-37 
vitamins and their derivatives in the distal gut are still not fully elucidated. Here we briefly review 38 
the function of single B-vitamin in the distal gut including their roles in relation to bacteria. The 39 





1 Introduction 43 
Recent studies have highlighted the presence of trillions of microbes in the guts of 44 
mammals; these bacteria produce several metabolites that play a significant role in the biological 45 
processes within the host.[1–8] Studies of the gut bacterium and specific isolated bacteria, particularly 46 
Bifidobacterium and Lactobacillus species, show that intestinal bacterium produce 7 of the 8 B-47 
vitamins.[9-20] B-vitamins are biosynthetic precursors of universally essential cofactors used in 48 
numerous metabolic pathways; they are indispensable to the host and gut microbiota alike. With the 49 
exception of niacin (vitamin B3), a mammalian host cannot produce B-vitamins de novo; there is a 50 
strict dependence on an exogenous supply, including from the diet and the gut microbiota (Figure 1). 51 
Although it has been thought that B-vitamins are mainly absorbed from the small intestine, there are 52 
many B-vitamin transporters expressed in the colon (Table 1).[21,22] The majority of microbes exist in 53 
the large intestine; they can be categorized as B-vitamin-producing bacteria and auxotrophic bacteria. 54 
As a result, competition and symbiosis occur between the host and bacteria, as well as among 55 
bacteria, especially with respect to the auxotrophic species whose viability is strictly dependent on 56 
acquiring one or more B-vitamins. In silico analysis showed that 20-30% of the gut microbiota lack 57 
the capacity to produce essential B-vitamins.[23] Since B-vitamin production is under the control of 58 
dietary substrates, some gut bacterium may influence food choices of the host.[24] Moreover, a host 59 
with an imbalanced or unfavorable intestinal microbiome, referred to as ‘dysbiosis,’ might have 60 
altered B-vitamin metabolism in their gut. 61 
To date, a search of PubMed (www.ncbi.nlm.nih.gov/pubmed, accessed on February 28, 2020) 62 
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using the terms 'B-vitamin (B-vitamin, B1, B2, B3, B5, B6, B7, B9, B12, thiamin, riboflavin, niacin, 63 
pantothenic acid, pyridoxine, pyridoxal, pyroxamine, biotin, folate, folic acid, or cobalamin)’ and 64 
‘gut microbiota (or gut microbe)’ returned over 323 relevant published articles of which almost 27% 65 
were reviews. Despite there being some excellent recent reviews on this topic, our understanding of 66 
the physiological importance of B-vitamins in the distal colon has only been addressed in some 67 
reports.[25-28] Prior to development of the concept of ‘gut microbiota’ there had been numerous 68 
studies conducted in this field, including studies about bacteria in the hindgut with the potential for 69 
growth and vitamin-producing capacity in the host. The importance of gut bacteria as a source of 70 
vitamins has been demonstrated further by the observation that germ-free animals require dietary 71 
sources of various vitamins that are not required by conventional animals.[29,30] Rodents can practice 72 
coprophagy which may indirectly supply B-vitamins through the small intestine. It is therefore, this 73 
behavior only confirms the availability of B-vitamins in the fecal bacterial biomass and leaves open 74 
the question of the availability of B-vitamins in the distal gut in the non-coprophagic host. 75 
It is challenging to identify in vivo evidence about the functional roles of the B-vitamins in the 76 
distal gut from a much larger number of animals, from C. elegans to humans. Functional differences 77 
could exist between B-vitamins in the proximal gut and distal gut for the host, as well as gut 78 
microbiota; however, relatively little is known about functional roles of B-vitamin in distal gut. In 79 
this review, we focus on the role gut microbes have on modulating B-vitamin availability and the 80 
functional role of B-vitamin in the distal gut.  81 
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2 B-Vitamins 82 
 83 
2.1 Vitamin B1 (thiamin) 84 
Thiamin can be produced by gut bacteria in silico and in vitro.[12,31] It is estimated that gut 85 
microbial thiamin synthesis supplies approximately 2.3% of the daily human requirement of vitamin 86 
B1 from intracellular concentration of vitamin, weight of bacteria, and composition of the human gut 87 
microbiota (Table 1).[27] Four enzymes implicated in the biosynthesis pathway of thiamin are 88 
overrepresented in enterotype 2, which is one of the human gut microbiota compositional clusters 89 
enriched by Prevotella (Table2).[32] High-affinity thiamin transporters 1 and 2 which are capable of 90 
carrier-mediated absorption of thiamin have been identified in human colonic mucosa and epithelial 91 
cell lines. [33–37] However, there are no data about the actual importance of the supply of thiamin at 92 
the distal gut from gut microbiota to host. 93 
Thiamin is a biosynthetic precursor of thiamin pyrophosphate which is essential to carbohydrate 94 
metabolism and neural function. Recently, Kunisawa et al. reported that vitamin B1 is important for 95 
glycolysis-dependent host cells, especially in Peyer’s patch cells.[38] In this regard, a dietary vitamin 96 
B1 deficiency may affect host immune responses via the regulation of differentiation and 97 
proliferation of immune cells that may in turn influence the gut microbiota. The researchers also 98 
showed that feeding mice a vitamin B1-deficient diet causes a vitamin B1 deficiency after only a 99 
week. This suggests that the gut microbiota of mammalian hosts is capable of synthesizing only a 100 
minimal shortfall of thiamin under general conditions. In contrast, Acetobacter pomorum, a thiamin-101 
producing bacteria, can rescue the development of axenic flies in the absence of dietary thiamin 102 
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(Figure 1, Table 1).[39] Thiamin is also important to a specific gut bacterium, Bacteroides 103 
thetaiotaomicron in vitro (Figure 1, Table 2).[40] Thiamin biosynthesis and its transport system are 104 
critical to the growth of B. thetaiotaomicron. These results suggest that thiamin produced in gut 105 
microbiota have a specific role in the composition or function of the gut microbiome.   106 
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2.2 Vitamin B2 (riboflavin) 107 
 Excess dietary riboflavin, as well as riboflavin produced by commensal bacteria, comprise 108 
the riboflavin present in the distal gut (Figure 1). In addition to lactic acid bacteria which are well-109 
known for producing riboflavin in the gut, a genomic analysis of 256 species of human gut microbes 110 
found more than half (56%) of them conserve a group of genes for de novo riboflavin 111 
biosynthesis.[11,27] Mice and humans harbor the functional riboflavin transporter 3 in their large 112 
intestine (Table 1).[41,42] In our previous study, we observed that the riboflavin supplied from gut 113 
microbiota played a pivotal role in the host; the gut microbiota was able to provide compensatory 114 
riboflavin in the short-term when a dietary riboflavin deficiency was induced in mice (Figure 2, Table 115 
1).[43] The survival of axenic—but not conventional—Drosophila was significantly depressed when 116 
their diet lacked riboflavin [44]. Qi B et al. showed the importance of live bacteria being able to 117 
provide micronutrients in the gut, such as riboflavin, to Caenorhabditis elegans (Table 1). [45] 118 
Riboflavin supplementation increases the usability of heat-killed bacteria as food and promotes 119 
intestinal protease activity in C. elegans, suggesting that commensal bacteria are a source of 120 
riboflavin in C. elegans.  121 
An effect of riboflavin on the growth of extremely oxygen-sensitive bacteria (e.g., 122 
Faecalibacterium prausnitzii) as agents of electron transfer has been suggested.[46,47] Interestingly, F. 123 
prausnitzii do not encode genes involved in riboflavin biosynthesis.[48] Because oxygen stress is the 124 
main aggravator of anaerobic gut microbiota such as F. prausnitzii and Roseburia, the acquisition of 125 
riboflavin modifies the composition of gut microbiota. Indeed, a preliminary study showed that 126 
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dietary riboflavin supplementation for 14 days increased F. prausnitzii and concomitantly reduced E. 127 
coli. in a small group of adult volunteers.[47] 128 
The pyrimidine compounds 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil (5-OP-RU) and 129 
5-(2-oxoethylideneamino)-6-D-ribitylaminouracil (5-OE-RU) are highly potent activating ligands of 130 
the mucosal-associated invariant T (MAIT)-cell (Tables 1).[49,50] Both 5-OP-RU and 5-OE-RU are 131 
generated from the riboflavin precursor 5-amino-6-D-ribitylaminouracil through the riboflavin 132 
producing pathway in various microbes. Taken together, riboflavin produced in the gut microbiota 133 
has roles in numerous hosts. These roles include functioning as an essential nutrient; or as a 134 
modulator of bacterium fitness in the gut microbiota and immune function in host. (Figure 1). 135 
  136 
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2.3 Vitamin B3 (niacin) 137 
Niacin can be made from tryptophan in mammals as well as from intestinal bacteria [51–53]. 138 
Mammalian colonocytes possess a carrier-mediated mechanism for the uptake of niacin [54]. 139 
Exogenous expression of the human sodium-coupled monocarboxylate transporter 1 in oocytes can 140 
transport both nicotinate and its structural analogs, despite substrate selectivity being low (Table 141 
1).[55] Administration of microcapsules containing niacin, which release their contents at the 142 
ileocolonic region, increased serum niacin concentration in a dose-dependent manner in human 143 
subjects.[56] 144 
Niacin acts as an agonist of cell-surface receptors, niacin receptor 1, which is also known as 145 
the hydroxycarboxylic acid receptor 2 or G-protein-coupled receptor 109A. Although niacin was not 146 
considered a crucial ligand of this receptor, it is expressed in colonic epithelium and its physiological 147 
roles have been studied extensively.[28,57,58] A niacin deficiency results in intestinal inflammation and 148 
diarrhea.[59,60] Niacin also exhibits potent antioxidant and anti-inflammatory properties and acts as a 149 
modulator of intestinal barrier function and bacterial endotoxin production.[61–63] Therefore, niacin 150 
has a direct impact on gut microbiota. Indeed, both tryptophan and niacin (nicotinic acid and 151 
nicotinamide) treatment have been shown to revert the composition of the intestinal microbiota of 152 
angiotensin I converting enzyme (peptidyl-dipeptidase A) 2 (Ace2) mutant mice (Table 1) [64]. 153 
Furthermore, the intake of a microcapsule of niacin (900 to 3000 mg)—but not nicotinamide (30 to 154 
300 mg)—resulted in a significant increase in the population of Bacteroidetes (Figure 1, Table2).[56] 155 
Since Bacteroidetes are deficient in the enzymes nicotinamidase and nicotinamide 156 
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phosphoribosyltransferase, and luminal niacin—but not nicotinamide—facilitates growth of the 157 
Bacteroidetes species in the gut (Table 1).[53] Collectively, these results suggest that niacin may have 158 
a favorable effect on gut microbial composition in humans.  159 
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2.4 Vitamin B5 (pantothenic acid) 160 
 A genomic analysis of 256 representative organisms of human gut microbiota found that de 161 
novo synthesis of pantothenic acid is limited in Bacteroidetes and Proteobacteria genomes.[27] 162 
Spearman rank correlations suggest that an increased intake of pantothenic acid was related to an 163 
increased relative abundance of Actinobacteria, which do not possess the ability to synthesize 164 
pantothenate (Table 2).[27,65] In addition, Lactobacillus spp., Streptococcus spp., and Enterococcus 165 
spp., members of the pantothenate nonproducing Firmicutes phylum, require pantothenic acid for 166 
their growth in vitro (Figure 1, Table 2).[66–68] These reports suggest that a symbiosis exists in the 167 
distal gut between pantothenic acid-consuming bacteria and pantothenic acid-producing bacteria. A 168 
study has shown the absorption of pantothenic acid across the intestinal loop by sodium-dependent 169 
multivitamin transporters (SMVT, SLC5A6) as well as biotin; however, direct evidence is lacking 170 
with respect to the absorption of pantothenic acid across the colon. [69–71] Antibiotic-treated mice 171 
reportedly exhibit signs of a pantothenic acid deficiency (Figure 1, Table 1).[72] Open questions 172 
remain about whether pantothenic acid in the distal gut could be a nutrient for the host, and if its 173 
availability modulates the composition of the gut microbiota and host cell function. 174 
  175 
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2.5 Vitamin B6 (pyridoxine, pyridoxamine, pyridoxal) 176 
Pyridoxal 5’-phosphate (PLP), a common coenzyme form of vitamin B6, can be synthesized 177 
de novo via two routes.[27] The majority of Actinobacteria, Bacteroidetes, and Proteobacteria 178 
(approximately 50% of the 256 human gut microbiota [HGM] genomes) have at least one de novo 179 
biosynthetic pathway. Reduced concentrations of vitamin B6 in the colonic content of wild type 180 
(WT) mice (0.4 to 0.5 mg/100 g) that have been treated with antibiotics (0.1 to 0.2 mg/100 g) are 181 
disruptive to their gut microbiota.[73] The administration of probiotics (Bacteroides acidifaciens) in 182 
this context partially restored the amount of vitamin B6 in the colonic content of antibiotic-treated 183 
mice. Luminal metabolic analysis and shotgun DNA sequence analysis showed that the metabolic 184 
pathway of vitamin B6 is dynamically changed in various conditions.[74–76] The relative abundance of 185 
Blautia, Coprococcus, and Roseburia, which are lower in patients with schizophrenia compared with 186 
control patients, was negatively correlated with vitamin B6 metabolism-related genes (Table 2).[75] 187 
When a person resistant to atherosclerosis consumes a cholesterol-enriched diet, microbiome genes 188 
for vitamin B6 metabolism increase significantly. [74] Distal gut bacteria samples from lean 189 
individuals appear to be more involved in vitamin B6 synthesis than samples from obese people 190 
based on metaproteomics analysis (Table 2). [76] The maintenance of vitamin B6 biosynthesis in host 191 
cells are of great importance for various homeostatic processes in health and disease, including host 192 
immune responses (Figure 1).[77–79] Consistent with these reports, the estimated maximal percentage 193 
of the daily reference intake of pyridoxine is the highest (86%) of all the 8 B-vitamins[27] The carrier 194 
of vitamin B6 has yet to be determined, although it has been characterized as an energy- and 195 
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temperature- (but not Na-) dependent transporter of pyridoxine in young adult mouse colonic 196 
epithelial cells. [80] 197 
Two excellent reports have characterized functions of vitamin B6 in the gut microbiota. 198 
Scott, et al. showed that microbes integrate nutritional- and drug-cues in C. elegans (Table 1).[81] 199 
They found that PLP produced by commensal bacterium acts in concert with ribonucleotide 200 
metabolism to facilitate the effects of 5-fluorouracil, a drug used to treat colorectal cancer. Inhibition 201 
of bacterial ribonucleotide metabolism drastically antagonizes drug efficacy, while inhibition of 202 
deoxyribonucleotide metabolism improves it, an effect also regulated by dietary pyrimidines.[81] 203 
Administration of vitamin B6-producing bacteria (B. acidifaciens), attenuates the colonization of 204 
Salmonella. typhimurium and promotes recovery from gut inflammation in antibiotic-treated mice 205 
(Table 1).[73] It is conceivable that there is an interactive effect of vitamin synthesis and function in 206 
the gut microbiota. 207 
Mice with a severe vitamin B6 deficiency protected them against dextran sodium sulfate 208 
(DSS)-induced colitis.[82] Another study also investigated the effect of dietary vitamin B6 intake on 209 
colonic inflammation in the IL10-/- murine model of IBD.[83] This study is highly suggestive because 210 
both moderate vitamin B6 supplementation and mild depletion significantly attenuated the 211 
histological and molecular features of colonic inflammation. Accordingly, approximately 30% of 212 
patients with inflammatory bowel disease (IBD) show evidence of a vitamin B6 deficiency.[84] 213 
Therefore, vitamin B6 bioavailability in the gut has an indirect role on colonic inflammatory diseases 214 
which include gut infection with enteropathogens and IBD. The prime cause of this indirect effect of 215 
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tryptophan metabolites. Supplementation of tryptophan and its metabolite niacin (nicotinic acid and 216 
nicotinamide) can rescue intestinal inflammation in Ace2 knockout mice.[64] Conversion of 217 
pyridoxamine and pyridoxine to PLP—requiring flavin-mononucleotide (derived from vitamin B2) 218 
as a coenzyme—is an essential cofactor for two key enzymes used in the synthesis of niacin from 219 
tryptophan.[85] Moreover, the bacterial metabolites implicated include tryptamine, indole, and indole 220 
metabolites (i.e., indole-3-aldehyde, indole-3-acetic acid [from some Lactobacillus], indole-3-pyruvic 221 
acid, indole-3-acrylic acid [from Peptostreptococcus], indole-3-lactic acid [from Bifidobacterium 222 
longum subspecies], and indole-3-propionic acid), or the host metabolite kynurenine, that activates 223 
the aryl hydrocarbon receptor (AhR) as the physiological agonist.[86–91] Activation of the AhR 224 
pathway may ameliorate DSS-induced colitis in mice.[92] DSS-induced colitis was more severe in 225 
AhR knockout mice than in WT mice.[93] Dietary supplementation with 0.5% tryptophan reduced the 226 
severity of DSS-induced colitis and ameliorated symptoms in WT mice but not in AhR knockout 227 
mice.[94] The production and supply of tryptophan metabolites are complexly regulated by the dietary 228 
supply of tryptophan or other nutrients, and the composition of the gut microbiota, such that vitamin 229 
B6, B2 and/or B3 availability in the colon may play an important role in the production of tryptophan 230 
metabolites. 231 
  232 
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2.6 Vitamin B7 (biotin) 233 
A genomic analysis of 256 representative organisms of human gut microbiota found that 234 
40% were capable of de novo synthesis of the vitamin B7.[27] Studies have shown that the phylum 235 
Bacteroidetes (48/51 strains), Fusobacteria (13/14 strains), and Proteobacteria (29/38 strains) 236 
predicts the synthesis of biotin.[27,95] In contrast, even though Actinobacteria genomes lack an 237 
essential biotin biosynthesis gene, 19 of 23 (83%) of them contained a biotin transporter, indicating 238 
the need for biotin.[27] This result suggests the potential to control Actinobacteria-related diseases via 239 
regulating biotin availability in the gut.[96] Another study showed that four enzymes in the biotin 240 
biosynthesis pathway are overexpressed in Bacteroides enterotype (Table 2).[32] Absorption of biotin 241 
in both the small and large intestine occurs via a carrier-mediated process that involves the SMVT 242 
system encoded by the SLC5A6 gene.[70,71,97–100] The colonic absorption rate of biotin measured by 243 
[14-C] biotin or the in vivo intestinal loop showed that post-ileal biotin absorption was 8 to 12% as 244 
efficient as the absorption of biotin after oral dosing in pig.[101,102] Lipopolysaccharides inhibit 245 
colonic biotin uptake via interference with membrane expression of its transporter.[103] On the other 246 
hand, Hayashi et al. revealed that competition for biotin utilization exists between the host and 247 
bacteria (Figure 1, Table 1).[104] Lactobacillus murinus consumes and reduces available biotin in the 248 
gut and antibiotic-induced dysbiosis promotes alopecia in mice fed a biotin-deficient diet (Table 1 249 
and 2).[104] 250 
  251 
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2.7 Vitamin B9 (folate) 252 
The microflora of the gut, particularly Bacteroides, Bifidobacteria, Streptococcus, and 253 
Lactococcus spp. can synthesize folate as a common food fermentation product of carbohydrates 254 
during the growth.[15,105–109] A genomic analysis of 256 representative organisms of human gut 255 
microbiota estimated that 43% of microbes conserve de novo folate synthesis pathway genes [27]. 256 
Folate biosynthesized by bacteria can be absorbed by folate transporters in the rat, pig, and human 257 
colon.[110–113] Although there is no clear evidence at this time, two types of folate transporters are 258 
considered to work in colon, the human proton-coupled folate transporter (SLC46A1) and the 259 
reduced folate carrier (RFC; SLC19a1).[114–121] The capacity of the large intestine to absorb forms of 260 
folate , equivalent to at least 37%, 18%, or nearly 100% of the daily human need, was estimated via 261 
in silico, pig, and human studies, respectively.[27,111,113] Folate biosynthesis in gut bacteria and/or 262 
transport expression in host are affected by a low-carbohydrate diet, increased protein content, 263 
probiotic dietary factors that affect gut microbes (e.g., dietary folate, fiber, oligosaccharide, and/or 264 
drug), and prebiotic bacteria supplementation (e.g., Bifidobacteria). Based on these influential 265 
factors, the composition of gut microbiota and dietary intake interactively modulate the availability 266 
of folate from the colon to host (Table 2).[105,106,116,122,123] 267 
Of note, colonic folate also has a role despite that it does not affect plasma folate levels.[124] 268 
Virk B, et al. showed that modulating folate uptake, or the folate cycle in the gut bacteria via E. coli, 269 
but not in the host (C. elegans), affects the lifespan of host. E. coli mutants influence the lifespan of 270 
worms independently of E. coli growth. Metformin retards aging in C. elegans by altering folate and 271 
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methionine metabolism in E. coli (Table 1).[125] As observed in the fly, dysbiosis and the consequent 272 
overabundance of a specific bacterial group which does not produce folate, may be an important 273 
factor in aging (Table 1).[126] These results suggest that bacterial folate synthesis influences the 274 
lifespan of hosts by acting on microbial physiology without compromising the host’s folate status. 275 
The targeted mutation of the bifunctional dihydrofolate synthase/folylpolyglutamate synthase type 2 276 
(folC2) gene, essential to the folate synthesis pathway, reduced immunomodulatory histamine 277 
production and the anti-inflammatory effect of L. reuteri 6475 in a mouse model of acute colitis 278 
(Table 1).[127] Similarly, a microbial folC mutation reduced intestinal folate production, and increased 279 
mRNA expression levels of the folate receptor, RFC, in human colonoids.[128] Cancer cells use folate 280 
for growth, so the availability of folate in the distal gut has been associated with the proliferation of 281 
colorectal cancers.[129–133] Luminal folate, or folate-derived metabolites, have a role in the regulation 282 
of immune function.[28,134] The folate-related metabolite 6-formylpterin antagonizes MAIT cell 283 
effector function.[134] 284 
  285 
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2.8 Vitamin B12 (Cobalamin) 286 
The cobalamin biosynthetic pathway is present in 42% (110/256) of the HGM genomes and 287 
can be found in all Fusobacteria.[27] In contrast, it is rare in Actinobacteria and Proteobacteria and 288 
half of the Bacteroidetes genomes are missing this biosynthetic pathway. A HGM study showed that 289 
83% of bacteria (260/313 species) encode cobalamin-dependent enzymes.[135] Intriguingly, most of 290 
these 260 species lack the genes required to synthesize cobalamin. [135] In another report, 75.9% 291 
(410/540) of the bacteria were cobalamin-utilizing organisms and only half of those (209/410) 292 
possessed the cobalamin biosynthetic pathway.[136] These genome-based analyses indicate that those 293 
bacteria rely on cobalamin-uptake mechanisms to acquire sufficient levels of it from the surrounding 294 
environment. For example, Bacteroides thetaiotaomicron does not encode genes involved in the 295 
cobalamin biosynthetic pathway, but rather it has three homologs of the cobalamin transporter, 296 
btuB1, btu2B, and btuB3 and a cobalamin binding factor, BtuG2 (Figure 1, Table 1).[135] 297 
 Recently, three cobalamin binding proteins (IF, haptocorrin, and transcobalamin) have been 298 
shown to mediate cellular cobalamin up-take in adult mammals via three receptors (i.e., IF-cbl 299 
R/cubilin, asialoglycoprotein R, and transcobalamin receptor [TC-R]). Cobalamin transport systems 300 
have been reviewed in detail elsewhere.[137–140] However, cobalamin represents only a small portion 301 
(1.4%) of the total amount in human feces.[141] Therefore, it is doubtful whether colonic-derived 302 
cobalamin has a role in nutrition of the host. 303 
In addition to cobalamin, bacteria can produce a variety of corrinoid derivatives.[142–144] In 304 
the presence of many corrinoids, 7 cobalamin analogs were identified and quantitated in human feces 305 
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(Figure 1, Table 1) [141]. As if to have the ability to respond to it, human gut microbes likely encode at 306 
least 27 distinct corrinoid transporter families. [144,145] Supplementation of 3.94 µg/ml 307 
cyanocobalamin increased fecal cobalamin and reduced corrinoid analogs concomitant with a lower 308 
abundance of Bacteroides in mice (Table 2).[146] These results suggest that competition and exchanges 309 
of cobalamin and its analogs could potentially determine microbial fitness. [143,144,147] The functions of 310 
corrinoids have been studied in several reports and were thoroughly reviewed by Degnan, et 311 
al.[145,148,149] Cobalamin and its derivatives determine not only microbial fitness, but also microbial 312 
activity, including pathogenicity in the host. The bacterial transcription factor EutR requires ethanol 313 
amine, a precursor of cobalamin, and the cobalamin derivative adenosylcobalamin for the 314 
transcription of virulence factors needed for infection of the host and dissemination of 315 
enterohemorrhagic E. coli (EHEC) serotype O157:H7 and Salmonella.[150–153] Cobalamin uptake by 316 
the gut commensal bacteria B. thetaiotaomicron limits the production of Shiga-Toxin by EHEC [154]. 317 
Cobalamin also acts as an immunomodulator to promote cellular immunity.[28,155,156] These results 318 
indicated that luminal cobalamin and the availability of its analog can modulate the luminal infection. 319 
  320 
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3 Analytical methods 321 
The use of novel and sophisticated methodology will be key to uncovering all the functional 322 
roles of B-vitamins and their metabolites in distal colon (Table 3). For example, mass spectrometry 323 
will be a powerful tool to find for novel metabolites derived from B-vitamins, as reported in corrinoid 324 
derivatives. Isotopic tracing techniques could assess metabolism and uptake of B-vitamins by 325 
bacteria and the host in the distal gut. Developing the experimental condition that prevent indirect 326 
supply of B-vitamins and its derivatives from fecal bacterial biomass in coprophagic rodents should 327 
be also considered. 328 
  329 
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4 Conclusions 330 
In the distal colon, B-vitamins derived from food and the microbiota help to nourish the host 331 
(Figure 1). The amounts of B-vitamins will be different depending on the composition of the gut 332 
microbiota. Within the intestinal microbiota, some bacteria utilize rather than synthesize B-vitamins 333 
which indicates that bacteria compete in the gut. Microbes also produce other metabolites from B-334 
vitamins that have significant roles in biological processes in the host or bacteria. Because the gut 335 
microbiota varies among individuals, the amounts of each B-vitamin in the distal colon will be 336 
different among the host and the populations of bacteria. Further investigations in this field, including 337 
interactive effects of multiple B-vitamins are warranted. Potentially other metabolites, derived from 338 
B-vitamins, play significant roles in the regulation of luminal health or dysregulation (Figure 1). Gut 339 
microbiota may synthesize specific metabolites that help us to sense whenever a nutrient is 340 
undersupplied, and related signaling or signs could influence our food choices.  341 
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Figure Legends 632 
Figure 1. The role gut microbes have on modulating B-vitamin and its derivatives availability and 633 
the functional role of those in the distal gut. 634 
B-vitamins are synthesized by intestinal microbiota and supply the host and other microbes. When 635 
gut microbes metabolize the B-vitamins they are converted into other compounds which have roles 636 
both in host cells and in microbes. Biosynthesized B-vitamins, and their metabolic derivatives, are 637 
excreted into the feces where they may be reused by animals that are coprophagic. 638 
Figure 2. Time course of the changes in riboflavin (left) and metabolism (right) in the luminal and 639 
host when riboflavin deficient diet ingestion. Luminal metabolic changes rapidly occur than in the 640 
host. Conc, concentration. 641 
32 
 
Table 1 Importance of B-vitamin in distal gut 642 
a) DRI were estimated in Magnúsdóttir S, et al.[27] There is a limitation in this estimation of DRI which did not consider the fact that B-vitamins 643 
produced by gut bacteria not only supply the host, but also supply other gut bacteria. 644 
Vitamin DRIa Colon transporter 
(official symbol)b 
Importance of B vitamin in distal gut  
B1, thiamin 2.3% THTR1 (SLC19A2) 
THTR2 (SLC19A3) 
• Supplies D. melanogaster with nutrients*[39] 
 
B2, riboflavin 2.8% RFVT3 
(SLC52A3) 
• Supplies mice with nutrients[43] 
• Supports survival of D. melanogaster* and C. elegans*[44,45] 
• Supports electron transfer in oxygen sensitive bacteria[46,47] 
• Metabolites activate MAIT-cells by derived from a riboflavin precursor[49,50] 
B3, niacin 27% SMCT1 (SLC5A8), 
GPR109A (HCAR2) 
• Helps growth of Bacteroidetes[53] 
 




86% N.D. • Manipulates the therapeutic potential of 5-FU in C. elegans*[81] 
• Suppresses colonization of pathogenic bacteria in mice[73] 
• Modulates colitis experimentally in mice[74–86] 
B7, biotin 4.5% SMVT, (SLC5A6) • Supplies mice with nutrients[104] 
B9, folate 
 
37% hPCFT (SLC46A1) 
Rfc1 (SLC19A1) 
• Folate metabolism in the gut microbiota modulates host aging and life span[124,125] 
• Helps the anti-inflammatory function of Lactobacillus reuteri[127] 
• Folate and folate-derived metabolites regulate immune function[28,135] 
B12, cobalamin 
 
31% N.D.  
• Provides other functional corrinoids[136,145, 147-149] 




b) Mammalian vitamin transporter in the colon was described. N. D.; not determined. 645 
* Depends on the differences in organ structure between insects and mammals, the results from D. melanogaster and C. elegans did not apply 646 
directly to mammals. 647 
5-FU, 5-fluorouracil; Ace2, angiotensin I converting enzyme (peptidyl-dipeptidase A) 2; DRI, dietary reference intake; HCAR2, hydroxycarboxylic 648 
acid receptor 2; hPCFT, human proton-coupled folate transporter; MAIT-cell, mucosal-associated invariant T-Cell; Rfc1, reduced folate carrier; 649 
RFVT3, riboflavin transporter; SMCT1, sodium-coupled monocarboxylate transporter 1; SMVT, sodium-dependent multivitamin transporter; 650 
THTR1, thiamin transporter1; THTR2, thiamin transporter 2.651 
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Table 2 Influence of B-vitamins on gut bacteria 652 
 653 
  654 
Vitamin  Relationship between B-vitamins and gut bacteria  
B1, thiamin • Biosynthesis pathway of thiamin were overrepresented in Prevotella 
enterotype[32]. 
• Critical for the growth of B. thetaiotaomicron in vitro[40] 
B2, riboflavin • Dietary riboflavin supplementation increased F. prausnitzii[47] 
• Open questions 
B3, niacin • A microcapsule of niacin (900 to 3000 mg) resulted in a significant 
increase in the population of Bacteroidetes[56] 
• Nicotinamide supplementation with drink improved the composition of 
the gut microbiota in Ace2 (-/-) mice[64] 
B5, pantothenic acid • Increased intake of pantothenic acid was related to an increased 
relative abundance of Actinobacteria[65] 
• Lactobacillus spp., Streptococcus spp., and Enterococcus spp., 
required pantothenic acid for their growth in vitro [66-68].  
• Open questions 
B6, pyridoxine, 
pyridoxamine, pyridoxal 
• The relative abundance of Blautia, Coprococcus, and Roseburia was 
negatively correlated with vitamin B6 metabolism-related genes[75]. 
• Distal gut bacteria samples from lean individuals appear to be more 
involved in vitamin B6 synthesis concomitant with lower ratio of 
Firmicutes/Bacteroides [76]. 
B7, biotin • Biotin biosynthesis pathway are overexpressed in Bacteroides 
enterotype[32]. 
• Critical for the growth of Lactobacillus murinus [104] 
B9, folate 
 
• Abundance of Bifidobacterium and Lactobacillus was positively 
associated with folate status[105].  
• Increased total aerobic bacteria was related to an increased total amount 
of folate in the intestinal content[106]. 
B12, cobalamin 
 
• Supplies nutrients for B. thetaiotaomicron in vitro [135] 
• Supplementation of cyanocobalamin increased fecal cobalamin 
concomitant with a lower abundance of Bacteroides[146]. 
Open questions remain whether indicated B-vitamin availability in the distal gut modulates the 
composition of the gut microbiota. 
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Table 3 Methods that could facilitate the uncovering of novel information in the future 655 
 656 
 657 
1. Mass spectrometry (MS): 
− MS can distinguish B-vitamins from metabolic derivatives (e.g., cobalamin 
from other corrinoids). 
− MS will be instrumental in the search for novel, or as yet untargeted, 
metabolites from which new biomarkers might be identified to elucidate the 
environment inside the gut. 
2. Experimental conditions for animal studies: 
− Coprophagy should be taken into account as it has the potential to alter fecal 
metabolites and dietary intake of vitamins to confound study results. 
− Housing rodents in metal cages or restrainers can help to avoid this. 
3. Isotopic tracing techniques: 
− B-vitamins and their metabolites could be quantitatively profiled using 
isotopes; B-vitamin transport could be traced to assess their metabolism and 
uptake by bacteria and the host. 
4. Transporters and receptors: 
− The functions of B-vitamin transporters expressed in the large intestine are 
unclear, particularly in a complex environment such as the mammalian 
colon. 
− Being able to specifically knockout or inhibit a gene within the large 
intestine could improve our understanding in relation to functionality. 
5. Reconstruction of the condition of the lumen: 
− Complicated processes, such as secretion, can utilize B-vitamins or B-
vitamin metabolites synthesized by bacteria. 


B-vitamins and their metabolic derivatives in the distal colon perform many 
important functions in the body; they act as (1) nutrients for a host and their 
microbiota, (2) regulators of immune cell activity and modulators of colitis, (3) 
mediators of drug efficacy, (4) supporters of survival, or the fitness of certain 
bacterium, and (5) suppressors of colonization by pathogenic bacteria.
